GI
PGNX

GAMCO Investors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

GAMCO Investors’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-17,000
Closed -$108K – 830
2016
Q3 		$108K Sell
17,000
-8,000
-32% -$48.4K ﹤0.01% 791
2016
Q2 		$106K Buy
+25,000
New +$121K ﹤0.01% 798

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GAMCO Investors's PGNX Position: Q4 2016 in Review

GAMCO Investors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2016, closing a stake of 17,000 shares — an estimated $108K sold.

GAMCO Investors first reported a position in PGNX in Q2 2016 and held it in 2 quarters. The position peaked at $108K in Q3 2016. 126 funds tracked by Wall St. Rank hold PGNX as of Q4 2016.

  • GAMCO Investors reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
  • GAMCO Investors sold 17,000 Progenics Pharmaceuticals Inc shares in Q4 2016, an estimated $108K.
  • GAMCO Investors first reported a position in Progenics Pharmaceuticals Inc in Q2 2016 and held it in 2 quarters.
  • GAMCO Investors's Progenics Pharmaceuticals Inc position peaked at $108K in Q3 2016.
  • 126 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2016.

Based on GAMCO Investors's 13F filing for Q4 2016, filed 10 Feb 2017.